Almac Secures New Metagenomics and Enzyme Discovery Programme with UCL

News   May 15, 2013

 
Almac Secures New Metagenomics and Enzyme Discovery Programme with UCL
 
 
 
 

RELATED ARTICLES

CRISPR Reveals New Targets for Promising Cancer Drugs

News

Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.

READ MORE

BioAscent Announces New CEO and Plans to Expand Discovery Services Offering

News

BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.

READ MORE

Cell Recycling System Offers Therapeutic Entry Point for Rare Disease Treatment

News

Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE